Repligen plunges on expected US FDA rejection of MRI pancreas agent
This article was originally published in Scrip
Shares of Repligen plummeted 45%, or $3.26, on 26 April after the firm revealed it expects to receive a rejection from the US FDA on the company’s new drug application (NDA) for RG1068, a synthetic version of human secretin, as an agent to detect pancreatic duct abnormalities in combination with MRI in patients with pancreatitis.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.